Endo International PLC (NASDAQ:ENDP) had its price objective lowered by stock analysts at Mizuho from $29.00 to $25.00 in a report issued on Friday. The firm currently has a “buy” rating on the stock. Mizuho’s price target indicates a potential upside of 43.02% from the company’s current price.

Several other brokerages have also weighed in on ENDP. Northland Securities upgraded Endo International PLC from a “market perform” rating to an “outperform” rating and set a $27.00 price objective for the company in a research report on Thursday, September 29th. Vetr cut Endo International PLC from a “hold” rating to a “strong sell” rating and set a $18.21 price target on the stock. in a research note on Tuesday, August 9th. Oppenheimer Holdings Inc. restated a “market perform” rating on shares of Endo International PLC in a research note on Tuesday, September 27th. Piper Jaffray Cos. restated a “neutral” rating and set a $19.00 price target on shares of Endo International PLC in a research note on Tuesday, September 27th. Finally, Citigroup Inc. decreased their price target on Endo International PLC from $40.00 to $25.00 and set a “buy” rating on the stock in a research note on Friday, September 16th. One research analyst has rated the stock with a sell rating, nine have given a hold rating, fourteen have issued a buy rating and one has issued a strong buy rating to the company. The company currently has an average rating of “Buy” and an average target price of $33.52.

Analyst Recommendations for Endo International PLC (NASDAQ:ENDP)

Endo International PLC (NASDAQ:ENDP) opened at 17.48 on Friday. Endo International PLC has a 52 week low of $12.56 and a 52 week high of $63.71. The stock’s market capitalization is $3.89 billion. The company’s 50-day moving average price is $19.69 and its 200 day moving average price is $19.15.

Endo International PLC (NASDAQ:ENDP) last issued its quarterly earnings data on Tuesday, November 8th. The company reported $1.01 earnings per share for the quarter, topping the consensus estimate of $0.81 by $0.20. The company earned $894.30 million during the quarter, compared to analyst estimates of $862.47 million. Endo International PLC had a positive return on equity of 15.95% and a negative net margin of 3.32%. The firm’s revenue for the quarter was up 18.6% compared to the same quarter last year. During the same period in the prior year, the business posted $1.02 earnings per share. Equities research analysts expect that Endo International PLC will post $4.55 EPS for the current fiscal year.

Several large investors have recently bought and sold shares of ENDP. World Asset Management Inc increased its stake in Endo International PLC by 0.8% in the third quarter. World Asset Management Inc now owns 19,432 shares of the company’s stock worth $392,000 after buying an additional 158 shares during the last quarter. Advantus Capital Management Inc increased its stake in Endo International PLC by 2.4% in the second quarter. Advantus Capital Management Inc now owns 19,932 shares of the company’s stock worth $311,000 after buying an additional 461 shares during the last quarter. Riverhead Capital Management LLC increased its stake in Endo International PLC by 5.5% in the first quarter. Riverhead Capital Management LLC now owns 32,435 shares of the company’s stock worth $913,000 after buying an additional 1,694 shares during the last quarter. Canada Pension Plan Investment Board increased its stake in Endo International PLC by 33.0% in the first quarter. Canada Pension Plan Investment Board now owns 9,019 shares of the company’s stock worth $254,000 after buying an additional 2,237 shares during the last quarter. Finally, Oakbrook Investments LLC increased its stake in Endo International PLC by 12.7% in the second quarter. Oakbrook Investments LLC now owns 26,150 shares of the company’s stock worth $408,000 after buying an additional 2,950 shares during the last quarter. Institutional investors own 96.61% of the company’s stock.

Endo International PLC Company Profile

Endo International PLC, formerly Endo Health Solutions Inc is a specialty healthcare solutions company focused on branded and generic pharmaceuticals, devices and services. The Company has a portfolio of branded pharmaceuticals that includes brands, such as Lidoderm, Opana ER, Voltaren Gel, Percocet, Frova, Supprelin LA, Vantas, Valstar and Fortesta Gel.

5 Day Chart for NASDAQ:ENDP

Receive News & Stock Ratings for Endo International PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International PLC and related stocks with our FREE daily email newsletter.